Dingdang Health Technology Group Ltd. (DINGDANG HEALTH) filed a Next Day Disclosure Return to the Hong Kong Stock Exchange on 7 July 2026, detailing a series of on-market share repurchases executed between 19 May and 7 July.
Key takeaways 1. Capital base intact—for now • Issued share capital remained at 1.25 billion ordinary shares as of 7 July 2026, with no new shares issued and no treasury shares held. • A total of 14.28 million shares (approximately 1.14 % of the existing share count) have been bought back for cancellation but were still outstanding at the reporting date; cancellation is pending.
2. Latest daily transaction • On 7 July 2026, the company repurchased 250,000 shares on the Exchange at prices between HK$0.93 and HK$0.95, spending HK$0.24 million. • This brings cumulative repurchases disclosed in the return to 14.28 million shares, acquired at prices ranging from HK$0.8281 to HK$0.9685 per share.
3. Headroom under current mandate • Shareholders approved a new 10 % repurchase mandate on 23 June 2026, authorising the company to buy back up to 124.32 million shares. • Since that date, 2.80 million shares—about 0.23 % of the issued capital at mandate date—have been repurchased, leaving more than 121 million shares of remaining capacity. • A 30-day moratorium on new share issues or treasury-share sales applies until 6 August 2026 following the latest buy-back.
4. Next steps • Upon formal cancellation of the 14.28 million repurchased shares, the outstanding share count would fall to roughly 1.24 billion, modestly enhancing earnings per share for existing shareholders. • All buy-backs were authorised by the board and executed in compliance with Hong Kong listing rules, according to the company’s filing.
The disclosure underscores DINGDANG HEALTH’s continued use of share repurchases as a capital-management tool, operating well within its approved mandate while signaling confidence in the company’s valuation.
Comments